Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Cronista

Published November 14, 2026 · Updated November 15, 2026

The U.S. government will invest $4.9 million in a “rapid-acting” psychedelic drug for war ...

Read the full story at Cronista

The investment is part of a broader strategy to speed up the study of psychedelic drugs and other therapeutic alternatives that could be used to treat.

Surfaced by 2 Google Alerts

  • Psychedelics
  • Ibogaine